Drug cocktail aims to shrink tumors before lung cancer surgery
NCT ID NCT03366766
Summary
This study tested whether giving a combination of drugs before surgery could better treat early-stage lung cancer. The treatment included an immunotherapy drug (nivolumab) plus standard chemotherapy drugs. The goal was to shrink tumors before surgical removal, potentially improving outcomes for patients with operable lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abington Hospital - Jefferson Health
Abington, Pennsylvania, 19001, United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.